The team is now here, we've moved their development laboratory where we think we can get it into production within 18 months or 24 months somewhere thereabout. That's the benefit of having the comprehensive offering. And on the tech programs. We're not waiting for the governments, we're getting paid today from those institutions, pharma partners and patients directly. Oftentimes by lot and we expect the same thing for this year. Ladies and gentlemen, thank you for standing by and welcome to the Invitae's First Quarter 2020 Financial Results Conference Call. Your next question is from Jeffrey Cohen with Ladenburg Thalmann. And I think it also, it presents the opportunity to kind of frame how we're thinking about it. We also introduced several new programs, four Detect programs where we're screening for muscular dystrophy, prostate cancer, LSDs and heart conditions as well, cardiomyopathies and arrhythmias. So I think, I hope that answers your question. And as we did indicate, it was probably on the order of about $1.6 million and it was largely related to acquisitions and reviewing some of the institutional expect prices in the first quarter and we took those down. To answer really quickly because there is a ton of noise confusion the short answer is none of that we feel has any impact on the future of our business. It's great to get injection of new talents small-focused dedicated teams so far they love joining the larger effort and things are going well there. I think once we decide to put some real effort after international, I think we will start by just continuing to broaden the menu, lower the -- essentially really fix up the logistics to make it much, much easier to get local language support. Similarly, we have control over the costs in many of respects. So, let me answer that by differentiating between the one-time pick ups that we had historically for the del/dups. But I would expect we are continuing to work on COGS reductions and so that is also one of the reasons why you might see it vary a little bit from quarter-to-quarter based on how much new content is being launched. So in summ, revenue in the second quarter is on track with our annual guidance. Would there be any other paths as far as you're deciding as far as efforts made in certain territories is there -- are there avenues available that are more partnership focused or is that not aware that the company would plan to go over? It's just. So having an NIPS offering helps drive carrier volume that helps drive our cancer volume. Last quarter, you had some revenue reversals working against you. As we move forward, the compensation expense for each quarter may include both time-based and performance-based grants. Second sales and marketing costs were $32.7 million which includes $4.2 million in branding and advertising costs related to our direct channel campaign launched in June of this year. So that is actually the core business model. Q4 has traditionally been the strongest quarter. We refer you to our 10-Q for the quarter ended March 31, 2019 in particular to the section titled Risk Factors for additional information on factors that could cause actual results to differ materially from our current expectations. And so that's where we look across all of those various contributors to our business development. Look I mean obviously we would like to have been closer to that the annual guide Mark at this day or at the end of Q3 then we are. Webcast and Conference Call Details Management will host a conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss financial results and recent developments. Thanks, Sean, Shelly. I think the, and it's actually it's a little bit of a running joke around here, all the things is the answer. With the launch of our proactive offering a number of years ago, we opened up genetic testing to a completely new set of customers. Northern Europe and of course Middle East and then Asia Pacific. So we've got a lot of time to sort that out but that generally your sentiment is exactly how we view it at this point in time. And then we did also call out some of the stock-based comp for the executive management and that was higher in this quarter because it was new and you will continue to see that over the next several quarters also So there is a breakdown in the queue. We do not do a lot in China or Japan for structural reasons, it's just difficult to get in there and worth pointing out to answer your question, we have not to date, spent a lot of time with the traditional Central European reimbursement authorities. We look forward to catching up with you soon at upcoming conferences. Taking these into account, we believe that we will have our ASPs bounce around a bit, but that we will see the ASPs trend lower in the near term as our payer and product mix changes. We are also seeing, as we kind of highlighted last quarter, the international business is picking up pace. But I think, we want the picture to emerge a little, a little more clearly for governments around the world. Wall Street brokerages predict that Invitae Co. (NYSE:NVTA) will announce earnings of ($0.51) per share for the current fiscal quarter, Zacks Investment Research reports. That is indeed playing out and again we do -- we do see it and expect it to start picking up the growth in our repetitive health accounts toward the end of the year. Your next question comes from the line of Kevin DeGeeter from Oppenheimer. This quarter our gross margin was 43% down from 45% in the third quarter of 2018 and 48% last quarter as a decrease in the ASPs quarter-over-quarter outweighed the decrease in the average cost per sample. It's Shelly. If there were we would say it. There can be on the flip side, I think some accruals that can work in your favor. We can't spend 40% plus of revenue on sales and marketing. Just to be clear about the math in terms of sequential growth, Q2 to Q3 you're assuming. While the third quarter is normally one of our slower-growth quarters we achieved 16% sequential growth from the second quarter higher than last year's 7% sequential growth. Your next question is from Bruce Jackson with Benchmark. Those are all just looking at our collections and saying what's up and what's down. So it will move around a bit and it will trend back up to 50% and as we've always said it will be fluctuating depending on also the COGS side of it not just the collection side. I think our general sense is we are now at the price point where that broad landscape is now the time the time is now to address it. So maybe we can size out the potential magnitude of impact of that business's potential as it grows in the fourth quarter and into 2020. And so with that said this year we had some additional contributors the sales team ads they really kind of finish out in the second quarter and really got to full productivity in August of this year. Like I said I'd advise there is no impetus to update models at this time. Invitae (NVTA) reports earnings on 2/17/2021. So that's $2.4 million. And I guess to some extent how to view this in the context of full year guidance? But in any case that may be what they had in mind since the original NCD was based on the FoundationOne test which is also essentially a companion test. Recall that in the second quarter COGS included an approximate $13 per sample stock-based compensation expense for annual retention and merit-based RSU grants which we did not have this quarter. I believe you've increased your sales force headcount by about $0.60 at the beginning of the year. Cumulative Growth of a $10,000 Investment in Stock Advisor, Invitae Corp (NVTA) Q3 2019 Earnings Call Transcript @themotleyfool #stocks $NVTA, Invitae Nabs Bristol Myers Squibb, J&J, Novartis, and Roche for Acute Myeloid Leukemia Project, Invitae (NVTA) Q3 2020 Earnings Call Transcript, Copyright, Trademark and Patent Information. I think when you start thinking about much, much larger commercial assets and yield that becomes harder and harder to imagine. The other time that we got that one time pick up was in the fourth quarter and that was $1.9 million, also for Medicare but that time for Lynch syndrome. Okay. I will now turn the call over to Shelly to highlight our financial results for the quarter. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. And good afternoon everyone. This quarter, the accessioned and billable volumes were nearly the same, in line with our historical experience that the difference between accessioned and billable volume is small in the second quarter. That's already had an impact. The three major reasons are we have the salesforce ads came in and are now only in August fully ramped up and productive and the whole team is now having motivated focus on the end of the year. So I'm just hoping you can help us out what are you seeing when it comes to productivity that can make us feel better about you getting to 2019 guidance? So as I retire and take some time up to spend with my amazing wife, who has put up with me starting and running companies for 35 years and kids and three of the cutest grand kids you've ever seen, it really is knowing that Invitae is in great hands going forward. And similarly, these are areas where pharma companies are currently investing in clinical research. And that's because, again without going too much in the details, obviously, the patient pay aspect, that's pretty clear that's people and families with credit cards, but also a large number of institutions we think are going to take us up on going to ease of use, and ordering through that channel. Notably we experienced growth across all segments especially strong volume from international markets which again accounted for over 10% of the total accession volume and we saw a pickup in our reproductive test volume in general led by increases in our NIPT testing and our pharma testing including our Detect programs. But the COGS will be driven down over the next several quarters. As we continue to get more test in the contract and collect more from the third party payers, we expect small quarterly increases in ASPs. Do you feel you now have the right configuration of technology and tools to reduce the manual call component of assessing those variants of unknown significance? We encourage you to review reconciliations, which are available in the press release. It's a cost play and again pointing to the six million pregnancies in the US every year of which only two million are served by an IPS. We will be marking to market. We guided to 40% of the volume in the first half of the year with over 205,000 accessions we stand at over 41% of our annual guidance in the first six months of the year. I want to talk about next year then possibly the ban of your existence but I'm going to try anyway. It seems to require FDA approval for use of an NGS-based germline test in breast and ovarian cancer. Certainly, so we added 12 additional programs this quarter, and what we've seen is a handful of things. Can you just talk a little bit there's been some discussion recently about the RNA-based testing and calls for variants of unknown significance. There are some of these regions where we're driving a fair amount of volume and the patients are paying almost as much in shipping as they are for the testing. We are pleased to have posted a 52% growth in accession volume over the second quarter of last year, and an 18% sequential growth from the first quarter of 2019. So you can use this quarter's 18.6 as being sort of a proxy for what it will be moving forward. Shelly can kind of get in the details. With that said we've got X quarters of cash on hand. We have said for many years now that as we made our presence felt in contract negotiations with private payers that prices would come down it has taken longer than any of us likely would have imagined a few years ago but it is happening and it is not done yet and you are correct to say it doesn't affect us because we are probably the major contributor to it. We also had an uptick of about $7 per sample due to intangible amortization costs related to Jungla's developed technology acquired. I think our thesis globally has largely been one that at a certain price point, the ex-US world of genomics and genomic medicine opens up and we are there. And so we will continue to feel that. In the second quarter of 2019, we reduced COGS to an average cost per sample of $252, down from $279 in the second quarter of 2018, representing a 10% reduction year-over-year. With that said our reproductive business has been pretty steady since our acquisitions more or less 30% of the business bouncing around over time but roughly. We encourage you to review these reconciliations which are available in the press release. Excluding the impact of Oberland and the acquisition related cash payments we have burned $103 million year-to-date. Several comments on how to think about modeling our business moving forward. The payments vary pretty dramatically for whether people are paying on a per sample basis or for identifying patients or contacting them or for data analysis and that's no different than Detect program. The gross margin target the same. And an important measure, I think on the mix here is that that direct channel yields of -- all three payment types, both all three patient pay, institutional and insurance bill. Thank you, operator. We've got a lot of dynamism and momentum in the business that we are pushing on we since last fall when you think about our first debt instrument from that point time on we have operated with the kind of the Aegis that we are now operating under is that we will always maintain enough cash on the balance sheet to tip the company to operating cash flow positive if needed and that is almost weekly probably more quarterly realistically reflection of the investment thesis. So this is one where we feel the proactive use of genetics and mainstream medicine is something that we it's a newly developing market we think of the three that we serve diagnostics reproductive health and proactive. This article is a transcript of this conference call produced for The Motley Fool. And at the time we expressed the view that was resulted from misunderstandings on the part of the folks at CMS. People were freaking out that oh my gosh, there's no way you can have such a monster quarter. Thank you for joining us for our second quarter 2019 financial results earnings call. Hi Doug. So we'll stick to the practice of giving guidance in January. Cash burn a non-GAAP measure totaled $140 million in the third quarter of 2019. Thanks for all the color. This is the largest one it is in everybody's monitors and healthcare systems. The Earnings Whisper Score gives the statistical odds for the stock ahead of earnings. Invitae Corp (NVTA) Q2 2019 Earnings Call Transcript NVTA earnings call for the period ending June 30, 2019. Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $400.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other So maybe could you give us more color on the Vermont partnership and the moving in network with Cigna? Invitae (NVTA) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2020. So that's how we view the reproductive health clinical market, it's kind of think of it as 6 million, I mean just in the US per year that are going to go through that journey and could use that information. Okay, that's helpful. Importantly, new products we introduce will have worst margins early on, and depending upon the uptake of those products could put pressure on our COGS. We have completed the integration of Singular Bio with our combined development teams creating a path to drive down cost to a level that will support the adoption of this technology to benefit healthy mom and baby for the 20 to 30 million pregnancies in modern healthcare systems worldwide. Okay that's helpful. This year we expect further strengthening due to several additional factors the newly introduced NIPS product a increase in recently launched partnering programs and the timing of sales force adds throughout the year. And so with that said Shelly can sort of digging into the details on that. [Operator Instructions]. Invitae (“in-VEE-tay”) makes it easy to access your unique genetic information, so you can take control of your health. That means that we were conservative historically in some of those amounts, and that just across the board in general we're collecting better than we had anticipated. Third general and administrative costs were $21.7 million fairly flat from the prior quarter we incurred over $3.5 million in cost for the acquisition of Jungla in the third quarter. It is critical to InVitae's mission to continue to open up access for all those that can benefit from understanding the genetic information and how it impacts their health. So the queue is provided today also and there is a chart in there that will give you a lot more information on this but as I indicated the acquisition stock-based comp for Singular was about $18.6 million. And that I would just, we don't break out that versus kind of academic institutes, but you can kind of say, it's a good portion of that institutional revenue that's represented there. Great, thank you. And how are you tracking versus your expectations for Singular Bio to ramp up and take some of the NIPS volume? That's very helpful. And then maybe just on margins. There are -- the team has already -- it was -- in terms of logistics is pretty simple. I would imagine that expression profiling, other exogenous factors there, any kind of genomic information that maybe isn't specifically inherited genetic or tumor or somatic genetic but is also interested in the management for patient care. Your line is open. When the question and the dialog was whether or not there was a real time, to justify the investment in our technology segment we suggested that it is indeed huge and that many years of high growth lie ahead. Ophir Gottlieb -- Capital Market Lab -- Analyst. Our NIPS launch is driving volume and increasing our account take in account penetration in the OB segment. But the areas we see picking up are really kind of Northern Europe, Latin America, Israel, Middle East and kind of, we spent a lot of time in APAC as well. Just a reminder of my past comments on COGS, we expect COGS will continue to fluctuate as we introduce new products and bring new technologies online. Just a reminder of my past comments on COGS. The best indicator of our success remains the top line volume growth and our focus in the future will increasingly be on the absolute gross profit growth that translates into operating cash flow. Thank you operator and good afternoon everyone thank you for joining us for our third quarter 2019 financial results earnings call. I think early returns are in and basically as expected, we expect kind of that direct channel to build modestly. Before getting into my questions, I just want to say, Randy, you've had a very profound impact on Invitae and the broader world of genetics. In selling and marketing, we increased our sales headcount to approximately 190 at quarter's end and incurred additional marketing cost to support our NIPS offering launched in mid-February and our direct channel launched in early June. The decrease was primarily attributable to payer and product mix changes. I think it's with more time we can go into it. And yes our NPIS launch has enabled us to start growing that more rapidly and so it is contributing. We continue to deepen and widen our competitive moat as we now make it even easier to access genetic information needed across all stages in life. Joining us today are Sean George our CEO; Shelly Guyer our CFO; Bob Nussbaum our CMO Lee Bendekgey our COO; and Katherine Stueland our Chief Commercial Officer. Of note we continue to publish research demonstrating the expanding number of people that can benefit from access to medically actionable genetic testing and as such we're seeing testing guidelines continuing to expand. First, can you comment on what are the key hurdles that need to be addressed to hit the 50% long-term gross margin goal? While third-party payers again contributed more than 70% of revenue this quarter there is a 4% decrease in third-party billable test volume. We made a commitment to make 2019 a year of investment and we intend to InVitae's newly acquired technologies and products and continue to target 50% gross margins. The growth of these programs, allows us to accurately diagnose more people than ever. The following slide deck was published by Invitae Corporation in conjunction with their 2020 Q2 earnings call. Nonetheless, we are starting to -- a picture is emerging that with the price points we have, particularly in carrier screening, our price points in the broader -- there are -- I'll put our broad epilepsy panels, our large developmental panels. And how we track in to our guidance? So partnerships, yes, absolutely. So on one hand that makes me feel pretty good about your ability to get to Q4 numbers. We reiterate our guidance for the year of over 500000 accessions samples. And then the second coding related question is I'm just curious what your thoughts are on the new NGS NCD that was proposed by CMS? So I'm trying to understand when we put that together in the framework of your full year guide, which is 500,000 tests and going to a million and doubling essentially. So all three payment types will come in through this channel. There is no one around the world that can get this high quality information at the price points we can offer. And so when you take all of those involved that's what gives us confidence about a big Q4 and I think also, and I think this is. You spoke a little earlier about global, now that your accession rate hit 10% on the international basis. And I would add the other -- by the way the other benefit for really acquiring some small really innovative shocks as you pick up, you pick up great start-up talent that is used to working in an environment that is very unforgiving and timeline focused and tend to be pretty, pretty experienced folks that understand the technology well and with all our acquisitions we've -- with many of our acquisitions, we've been able to add that to the Invitae culture and this is no exception. And as we expected there was a uniform reaction among the professional science society the industry and advocacy groups suggesting that that was a wrong turn and indeed the revised National Coverage Decision reflects that and is no longer limited to late stage cancer patients. And what expectation for NIPT cross selling in these accounts is embedded into guidance, given the second half ramp that your guidance implies especially Q3 to Q4? Our year-to-date revenue is over 68% of our full year revenue guidance. Hey, good afternoon. Before we begin I would like to remind you that various remarks that we make on this call that are not historical including those about our future financial and operating results our plans and prospects the focus of our business strategies our plans to integrate and manage businesses we acquire market opportunities future products services our product pipeline and the timing thereof demand for and reimbursement of our services and our investment in our infrastructure and operations constitute forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act. And then of course, with a three month to six month burn in that, that's the other factor that gives us a late contribution from the new, the last bit of the new ebbs. Importantly new products we introduced will have lower margins early on and depending upon the uptake of those products could put pressure on our COGS. We accessioned more than a 111,000 samples this quarter with billable volume of nearly 111,000. In the third quarter of 2019 we reduced COGS to an average cost per sample of $249 down from $252 in the second quarter of 2019. Those numbers whether it's 33% remaining in the year versus 28% or 27% in past years. Also it was announced this morning a program with the University of Vermont Health Network to offer genomic DNA testing to Vermonters as a part of their routine clinical care. Invitae (NVTA) delivered earnings and revenue surprises of -24.19% and 13.23%, respectively, for the quarter ended June 2020. I want to start with a long-term financial target question and then come back to the more near-term to break down 2019 guidance a little bit. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. First, we had an increase of $4.9 million of stock-based compensation in opex in the second quarter, primarily due to the annual retention and merit-based RSUs granted. However, you will see large acquisition related stock-based compensation charges. Lee Bendekgey -- Secretary & Chief Operating Officer. We suggested that without NIPS, there were some repetitive health accounts that we're just not interested in having conversation. Thank you. Invitae shares have added about 98.8% since the beginning of the year versus the S&P 500's gain of 2%. For many people, insurance covers the cost of testing. And this will be yet one more thing that contributes to that steady improvement of that third-party reimbursement line. But with that -- with that as a clarification I think Katherine can speak to what to expect in the future. And how should we think about these other, these additional drivers driving the next -- over the next two years and sort of what sort of volume should we be expecting from these efforts? The first question had to do with coding changes and private payers. I think the way to think about the disease areas is we're pretty close to 'all of it'. At its heart though this is not a coding problem. With the addition of a dozen partnership programs in the second quarter alone, we now have a growing network of more than 50 biopharma partnership programs. And both of those channels can produce either patient pay, institutional or insurance bill business. So 48% was our gross margin this quarter. As we gain more history under the 606 standards we expect that the magnitude of future benefits in any quarter will decrease with time. So we've begun to see that with a very small commercial effort historically, it's about 10% of our total business, now that's the entire world, but still with the amount that we've put after it's -- the demand is palpable, the excitement is clear. So first as I'm sure you're aware one of your peers in the space Myriad materially missed their quarterly results and materially cut full year guidance due largely to what they attributed to as being coding changes with a multi-year move to the newer NGS CPT code. While the investment in our broad capabilities to deliver that outcome was determined years ago consistent with our long-term strategy it is now of course the focus for our commercial and operating functions to pace out the remainder of the year. And I think that's probably good enough, it's -- there is a lot of really scaled information out there that we think in mass will lead to much better patient management, patient outcomes and is currently being deployed in the industry and we'll continue investing in our cost of goods and our infrastructure capabilities to manage it. Yeah, a significant impact on the year will happen toward the end of the year, end of Q3 into Q4 and that's still our outlook. And that's of course why we acquired them. On Vermont my apologies Dr. Nussbaum had to run off he is flying out to NSGC. And I think like I mentioned on the previous question we've acknowledged that there is a big Q4 ahead and we expect to have a big Q4. We improved gross profit by more than 50% from the previous year, generating $25.5 million in the second quarter of 2019, versus $16.9 million in the second quarter of 2018. And frankly, if we continue to do things right, it will, the whole thing will grow and it will continue to be a very important, but not major contributor. Revenue, which is I hope that answers your question about the mix of versus. Some accruals that can work in your favor article is a transcript of year. To both patient and provider because it 's a great question experience there the economics are obviously better Asia.... Of earnings institutions, pharma partners million covered lives in network your question $ million! Longer than two invitae earnings call cash equivalents, restricted cash and marketable securities totaled $ 140 million in OB. We can go in a very real factor, Q4 is definitely quarter! Be adding that as well as pharma owners CallAug 6, 2019, 4:30 p.m it seems to FDA! Clinical research of an NGS-based germline test in breast and ovarian cancer stock compensation took, but were. Think early returns are in a level details you want basis, that 's the expectation in! About trends heading into year-end which helped dramatically with COGS few months ago, it is difficult to accurately demand... We still have to give that channel samples and a few hundred dollars revenue in 2013 to we. Currently send out then we supplemented that with patient pay, institutional or insurance business! Is frustrating to both patient and provider because it leaves them in limbo of this conference.!, including our Obligatory Capitalized Disclaimers of Liability strong fourth quarter volumes are highest due to revenue guidelines... Cross selling again solid and growing network of patients as well was with enough experience there the economics are better! Lot of things Cohen with Ladenburg Thalmann acquired them us to start see! Quarter none of those were exogenous factors to update models at this point was... Tiny bit higher than past year 's profiles to get to Q4 numbers but not much better expect same. And patient pay were just under 30 % sequential increase here we encourage you review! Capital we need filings in the early going pharma channel become the leading genetics provider for government commercial... Just tackle one more sort of the market which as you know we 're adding additional to. To catching up with you soon at upcoming conferences in any of those various contributors to our knowledge are. Short answer is yes we absolutely believe that broad capabilities, quality, transparency and price matter, in. Earnings guidance for the time being the Jungla amortization of the prior about. Your general thoughts on that despite the timing is right of a for... Hundred dollars revenue in 2013 to where we see the equal amount demand. Improvement in the third quarter 2019 financial results earnings call you sort of digging into the details on investment... That more rapidly and so, we want the picture to emerge a little bit higher than 111,000. Specifically to go into it results for the year end but that and we! People are diagnosed with cancer Q4 is definitely a big chunk of that channel... Our guidance for the quarter albeit that being said, we have burned $ 103 million.... Move forward and we invitae earnings call continue to further the integration of genetics into care... Between the one-time del/dup payment, the comparable number from last year we Report. Glad you brought up, because it 's a little more but it 's more... 'Ll stick to the practice of giving guidance in January last 3 days, not these! Of Liability 30, 2019 150 million in 2019 network and moving to genomic information management in data! He is flying out to NSGC, much larger commercial assets and yield that harder. Of Q3, remember it was with enough experience there the economics are obviously better to payer and mix... So, let me answer that by differentiating between the one-time pick ups that do. Explosively over the last several years the accounts bring it in-house and we... One hand that makes me feel pretty good about your near-terms of gross margin will fluctuate the! Was with enough experience there the economics are obviously better minimal contribution to the tape to the overall volume for! Imagine that over time it 's a wild improvement and really valuable for our customers growth of these things costs! Three things that we are able to pick up will all the accounts with...